06 August 2018 | News
Market is expected to reach $6.9 billion in 2022 due to its evolving role in companion diagnostics, finds Frost & Sullivan
Clinical laboratories' intensifying demand for a robust solution to manage data and the declining availability of skilled pathologists is making a strong case for the automation of tissue diagnostic systems.
Innovations in the automation of staining equipment and novel platforms such as digital immunohistochemistry (IHC) will be significant as automation and the use of an advanced laboratory information system (LIS) are emerging key differentiators in the global market.
There will also be strong investment activity in digitization, as digital formats can be integrated within the health information systems and made easily available for diagnostics purposes.
Frost & Sullivan's recent analysis, Global Tissue Diagnostics Market, Forecast to 2022, highlights key market participants, customer segments, and restraining factors such as liquid biopsy and reimbursement cuts.
It segments the market by pre-analytical staining, advanced staining, and APLIS across the United States, Western Europe, Asia-Pacific, and Rest of the World. This market is expected to register a CAGR of 7.9% from $4.7 billion in 2017 to $6.9 billion in 2022 due to its evolving role in companion diagnostics and use of automation.
Global Tissue Diagnostics Market, Forecast to 2022 is part of Frost & Sullivan's global Life Sciences Growth Partnership Service program.